Delcath Receives Orphan Drug Designation for Treatment of Neuroendocrine Tumors
Delcath Systems, Inc. has received orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for the use of high-dose melphalan in the treatment of neuroendocrine tumors, utilizing their proprietary drug-delivery system.
The drug-delivery system, Delcath Percutaneous Hepatic Perfusion (PHP) System™, is designed for the direct delivery of high-dose anticancer drugs to the liver. This is Delcath System’s third ODD, which also include high-dose melphalan for the treatment of patients with metastatic cutaneous or ocular melanoma.
Delcath Systems is currently enrolling patients in Phase II and Phase III clinical trials.
Treatment & Management of Ovarian Cancer
Understand the role of surgery, chemotherapy, and precision cancer medicines in the treatment of Ovarian Cancer.
Precision Cancer Medicines for Ovarian Cancer
Genomic testing identifies targets that can be treated with precision cancer medicines. ASCO 2021 update
Liquid Biopsies Replacing Tissue-based Tests and Improving Treatment
NGS and biomarker testing with liquid biopsies improve treatment and should be performed in all newly diagnosed NSCLC patients.
